Dealing with Endometriosis

Translate to Spanish or other 102 languages!

Endometriosis can start at a person’s first menstrual period and last until menopause. Image for illustration purposes
Endometriosis can start at a person’s first menstrual period and last until menopause. Image for illustration purposes
- Advertisement -

By Texas Tech University Health Sciences Center El Paso

Gynecology specialist Mary Ann Son, M.D. with Texas Tech Physicians of El Paso. Image Courtesy of  TTUHSC El Paso

Newswise — Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus. It can cause severe pain in the pelvis, cystic growths in the ovaries and other organ spaces, and makes it harder to get pregnant.

  • Endometriosis affects roughly 10% (190 million) of reproductive age women and girls globally.
  • Endometriosis can start at a person’s first menstrual period and last until menopause.
  • It is a chronic disease associated with severe, life-impacting pain during periods, sexual intercourse, bowel movements and/or urination.
  • Access to early diagnosis and effective treatment of endometriosis is important.
  • It is important to schedule an exam with an Ob Gyn to determine if you are at risk.
- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Sun Allergy Is Real: Signs, Causes, and How to Protect Your Skin

Is it possible to have a sun allergy? It may feel that way on a hot day, but for some people, that’s actually the case.

Beat the Summer Heat: Essential Hydration Tips

Summer heat has a way of sneaking up on you, making it easy to become dehydrated before you even realize you're thirsty.

STHS’ Transform Your Life Event Inspires Healthier Living Across the RGV

Whether you're making healthier food choices, becoming more active or focusing on your mental well-being, every positive change can help you live a longer, healthier and more fulfilling life.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.
- Advertisement -